Since the advent of the first CAR-T cell therapy in Novartis’ Kymriah, production issues have been a persistent limiting factor for these advanced therapies. Whether dealing with CAR-Ts or newer gene therapies, managing supply chain issues, ensuring patients can access treatment centers and simply having enough capacity on deck to produce bespoke doses continues to be front-of-mind for many developers. In this panel, we’ll talk about the latest innovations in cell therapy manufacturing, plus the production considerations necessary to ensure the success of a more recent roster of gene therapies. |
